PCIB PCI Biotech Holding ASA

PCI Biotech: Capital increase registered and listing of new shares

PCI Biotech: Capital increase registered and listing of new shares

Oslo, Norway, 8 September 2020. Reference is made to the previous announcements by PCI Biotech Holding ASA ("PCI Biotech" or the "Company") in respect of the issuance of 60,500 new shares following exercise of employee share options in the Company.

The share capital increase resolved by the Board of Directors following the share option exercise on 2 September 2020, has now been registered in the Norwegian Register of Business Enterprises, and the capital increase has thus been completed.

The Company's new share capital is NOK 111,979,170 divided by 37,326,390 shares, each with a nominal value of NOK 3.00 and each giving one vote at the Company's general meeting.

The new shares issued following the option exercise will be tradable when they have been registered on the VPS accounts of the subscribers; such registration is expected to be executed on or about 8  September 2020.

Contact information:

Per Walday, CEO, , Mobile:

For more information visit:

Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, Oslo, NO-0379 Norway

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

EN
08/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PCI Biotech Holding ASA

 PRESS RELEASE

PCI Biotech: Invitation to first half 2025 results presentation and co...

PCI Biotech: Invitation to first half 2025 results presentation and corporate update Oslo, Norway, 26 August 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2025 interim report on Friday, 29 August 2025, 08:30am – 09:00am CET (local time).  The presentation will be held in Norwegian as a live webcast available through There will be a Q&A session at the end of the presentation. Please submit questions to prior to the webcast. It will be possible to post written questions through the webcast console during the session. The interim report and ...

 PRESS RELEASE

Flaggemelding

Flaggemelding Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag solgt 2 000 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS ingen aksjer i PCI Biotech Holding ASA.

 PRESS RELEASE

Flaggemelding

Flaggemelding Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag kjøpt 240 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS 2 000 000 aksjer, noe som utgjør 5,36% av aksjene i PCI Biotech Holding ASA.

 PRESS RELEASE

PCI Biotech announces discontinuation of development of the PCL techno...

PCI Biotech announces discontinuation of development of the PCL technology and evaluation of future operations Oslo (Norway), 18 August 2025 – PCI Biotech Holding ASA (PCI Biotech, OSE:PCIB) today announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector manufacturing.  Today’s decision is primarily based on the insufficient progress towards the 2025 goal of demonstrating improved yield in mini benchtop bioreactors. Achieving successful end-to-end results in small bioreactors is a critical risk-reducing milestone for further development. Fol...

 PRESS RELEASE

PCI Biotech: Minutes of Annual General Meeting 2025

PCI Biotech: Minutes of Annual General Meeting 2025 Oslo, 22 May 2025. The Annual General Meeting in PCI Biotech Holding ASA took place today, 22 May 2025.  All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on Contact information:        PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo        Ronny Skuggedal, CEO / CFO, , Mobile: This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.  Attachment ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch